Latest news with #Omnipod®
Yahoo
6 days ago
- Business
- Yahoo
Kion Unveils New FinOps Governance Capabilities and Partnership with ProsperOps to Help Customers Maximize Cloud Value
New automation and policy capabilities empower FinOps teams to prevent waste, speed decision-making, and operate with confidence across multicloud SAN DIEGO, June 03, 2025--(BUSINESS WIRE)--FinOps X — Kion, the leading automated CloudOps platform for multicloud, today announced the release of Kion version 3.13 alongside a new partnership with ProsperOps, a leading FinOps optimization platform. Through the partnership with ProsperOps and new Kion FinOps governance platform upgrades, Kion helps organizations simplify spend and budgets for faster decision making, apply usage policies to prevent cloud waste and automate FinOps governance and policy to drive efficiency across multicloud infrastructure. Kion v3.13 offers new features that provide better chargeback capabilities, a revamped dashboard experience, more powerful enforcements and additional user driven enhancements that make the platform easier to use and deliver value faster. These enhancements provide CloudOps and FinOps teams with more control over spend, enables faster anomaly detection and delivers a streamlined user experience. One of the company's newest customers, Insulet, the innovative medical device manufacturer of the Omnipod® insulin delivery platform, highlighted their reasons for selecting Kion: "We needed a governance tool that could go beyond generic FinOps capabilities and provide clear, actionable insight into cloud spend so we could drive accountability across teams. Kion came at the perfect time, delivering a single workflow with forecasting and budgeting capabilities. It immediately helped surface waste and cost anomalies that used to take days to track down and shifted the conversation from reactive to proactive, automated cost control," said Matt Cofran, Director of Cloud Operations, Insulet. Meeting the Needs of Regulated EnterprisesAs a self-hosted platform, Kion is uniquely suited for government agencies and enterprises with complex compliance, data sovereignty and regulation requirements. The partnership with ProsperOps allows FinOps teams to shift from reactive cost control to strategic financial operations. Kion unifies governance, automation and FinOps in a policy-based platform that works with ProsperOps automation, integrating rate and workload optimization to reduce risks, cloud costs and manual effort. Together, the two platforms provide a well-rounded efficiency solution that is advantageous to government agencies and highly regulated industries seeking FinOps optimization controls while also needing to streamline compliance with stringent federal security and operational requirements. "FinOps governance and waste reduction are top priorities for businesses. Yet, cloud cost optimization is still a major challenge largely due to a lack of visibility, understanding and allocation of cloud resources and usage," said David Roldan, Head of Partnerships and Alliances at ProsperOps. "By partnering with Kion, we're able to bridge the FinOps and CloudOps gap, bringing together the best of both worlds — the automation for cloud cost savings with the policy driven governance that teams need to run efficiently and confidently in the cloud." "We say that the future of FinOps is CloudOps because of the rising priority of FinOps governance and policy at scale. A robust cloud operations platform will enable both teams to work together to manage their multicloud environment without spinning up unintentional resources or running over budget," said Tatum Tummins, Senior Product Manager at Kion. "Kion is well positioned to support the future of FinOps by forging fruitful partnerships and advancing our FinOps governance and automation capabilities to help regulated organizations maximize cloud value and deliver AI innovation faster." Kion was recently recognized as an IDC Innovator for FinOps and Cloud Cost Transparency. According to the report, "Kion was chosen as an innovator in the marketplace because of its commitment to supporting the growing and evolving cloud market." The report notes Kion's key differentiators as; comprehensive cloud governance to help companies rapidly mature their FinOps teams, visibility and advanced automation and customer service. In addition to exhibiting at FinOps X, Kion will be exhibiting at AWS Summit, Washington DC on June 10-11. Stop by Kion's booth #348 to learn more about common CloudOps challenges, benefits of integrating FinOps into your CloudOps practices and new Kion capabilities that drive cloud efficiency for public sector IT leaders. Tummins will also be onsite for a Lightning Talk on Tuesday, June 10 at 2:35pm ET in the Apollo Theater covering "FinOps ROI Playbook: Do More with Less to Maximize Cloud Efficiency." About KionKion automates CloudOps with a single platform providing policy-based identity, FinOps, and compliance for multicloud infrastructure. Kion helps organizations achieve 'governance by default' through improved visibility, automation, guardrails, and guidance across multicloud environments. This helps enterprises reduce complexity, eliminate chaos, and minimize manual work so they can innovate faster with less risk. Wherever they are on their cloud journey, Kion empowers organizations to confidently provision accounts, maintain financial control, and ensure compliance with security regulations. Kion serves leading commercial, higher education, and government agencies including Indeed, Verizon, NASA, and the Centers for Disease Control and Prevention (CDC). View source version on Contacts Media Contact Natalie Sasscer301-751-5176LaunchTech CommunicationsNsasscer@ Sign in to access your portfolio
Business Wire
6 days ago
- Business
- Business Wire
Kion Unveils New FinOps Governance Capabilities and Partnership with ProsperOps to Help Customers Maximize Cloud Value
SAN DIEGO--(BUSINESS WIRE)-- FinOps X — Kion, the leading automated CloudOps platform for multicloud, today announced the release of Kion version 3.13 alongside a new partnership with ProsperOps, a leading FinOps optimization platform. Through the partnership with ProsperOps and new Kion FinOps governance platform upgrades, Kion helps organizations simplify spend and budgets for faster decision making, apply usage policies to prevent cloud waste and automate FinOps governance and policy to drive efficiency across multicloud infrastructure. Kion v3.13 offers new features that provide better chargeback capabilities, a revamped dashboard experience, more powerful enforcements and additional user driven enhancements that make the platform easier to use and deliver value faster. These enhancements provide CloudOps and FinOps teams with more control over spend, enables faster anomaly detection and delivers a streamlined user experience. One of the company's newest customers, Insulet, the innovative medical device manufacturer of the Omnipod® insulin delivery platform, highlighted their reasons for selecting Kion: 'We needed a governance tool that could go beyond generic FinOps capabilities and provide clear, actionable insight into cloud spend so we could drive accountability across teams. Kion came at the perfect time, delivering a single workflow with forecasting and budgeting capabilities. It immediately helped surface waste and cost anomalies that used to take days to track down and shifted the conversation from reactive to proactive, automated cost control,' said Matt Cofran, Director of Cloud Operations, Insulet. Meeting the Needs of Regulated Enterprises As a self-hosted platform, Kion is uniquely suited for government agencies and enterprises with complex compliance, data sovereignty and regulation requirements. The partnership with ProsperOps allows FinOps teams to shift from reactive cost control to strategic financial operations. Kion unifies governance, automation and FinOps in a policy-based platform that works with ProsperOps automation, integrating rate and workload optimization to reduce risks, cloud costs and manual effort. Together, the two platforms provide a well-rounded efficiency solution that is advantageous to government agencies and highly regulated industries seeking FinOps optimization controls while also needing to streamline compliance with stringent federal security and operational requirements. 'FinOps governance and waste reduction are top priorities for businesses. Yet, cloud cost optimization is still a major challenge largely due to a lack of visibility, understanding and allocation of cloud resources and usage,' said David Roldan, Head of Partnerships and Alliances at ProsperOps. 'By partnering with Kion, we're able to bridge the FinOps and CloudOps gap, bringing together the best of both worlds — the automation for cloud cost savings with the policy driven governance that teams need to run efficiently and confidently in the cloud.' "We say that the future of FinOps is CloudOps because of the rising priority of FinOps governance and policy at scale. A robust cloud operations platform will enable both teams to work together to manage their multicloud environment without spinning up unintentional resources or running over budget,' said Tatum Tummins, Senior Product Manager at Kion. 'Kion is well positioned to support the future of FinOps by forging fruitful partnerships and advancing our FinOps governance and automation capabilities to help regulated organizations maximize cloud value and deliver AI innovation faster.' Kion was recently recognized as an IDC Innovator for FinOps and Cloud Cost Transparency. According to the report, 'Kion was chosen as an innovator in the marketplace because of its commitment to supporting the growing and evolving cloud market.' The report notes Kion's key differentiators as; comprehensive cloud governance to help companies rapidly mature their FinOps teams, visibility and advanced automation and customer service. In addition to exhibiting at FinOps X, Kion will be exhibiting at AWS Summit, Washington DC on June 10-11. Stop by Kion's booth #348 to learn more about common CloudOps challenges, benefits of integrating FinOps into your CloudOps practices and new Kion capabilities that drive cloud efficiency for public sector IT leaders. Tummins will also be onsite for a Lightning Talk on Tuesday, June 10 at 2:35pm ET in the Apollo Theater covering 'FinOps ROI Playbook: Do More with Less to Maximize Cloud Efficiency.' About Kion Kion automates CloudOps with a single platform providing policy-based identity, FinOps, and compliance for multicloud infrastructure. Kion helps organizations achieve 'governance by default' through improved visibility, automation, guardrails, and guidance across multicloud environments. This helps enterprises reduce complexity, eliminate chaos, and minimize manual work so they can innovate faster with less risk. Wherever they are on their cloud journey, Kion empowers organizations to confidently provision accounts, maintain financial control, and ensure compliance with security regulations. Kion serves leading commercial, higher education, and government agencies including Indeed, Verizon, NASA, and the Centers for Disease Control and Prevention (CDC).
Business Wire
23-05-2025
- Business
- Business Wire
Insulet to Present at the Goldman Sachs 46 th Annual Global Healthcare Conference 2025
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced that management will present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 in Miami on Tuesday, June 10, 2025 at 9:20 a.m. (Eastern Time). To listen to the live audio webcast of the presentation, please visit A replay of the webcast will also be available following the event. About Insulet Corporation: Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet's flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit or ©2025 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation. All rights reserved.
Yahoo
23-05-2025
- Business
- Yahoo
Insulet to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025
ACTON, Mass., May 23, 2025--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 in Miami on Tuesday, June 10, 2025 at 9:20 a.m. (Eastern Time). To listen to the live audio webcast of the presentation, please visit A replay of the webcast will also be available following the event. About Insulet Corporation: Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet's flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit or ©2025 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation. All rights reserved. View source version on Contacts Investor Relations: June LazaroffSenior Director, Investor Relations(978) 600-7718jlazaroff@ Media: Angela Geryak WiczekSenior Director, Corporate Communications(978) 932-0611awiczek@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13-05-2025
- Business
- Yahoo
Insulet Announces Publication of 2024 Sustainability Report
ACTON, Mass., May 13, 2025--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, is proud to announce the publication of its 2024 Sustainability Report. This report underscores Insulet's unwavering commitment to sustainable practices and highlights significant achievements in environmental, social, and governance (ESG) initiatives. "At Insulet, our sustainability impact is inextricably tied to our mission as a company and our workplace culture. Through our products and innovative business models, we can make life simpler for millions of people with diabetes while improving health outcomes," said Vice President of Global Sustainability and Chief Sustainability Officer, Lisa Brady. "We remain steadfast in our commitment to creating positive change – for people with diabetes, for our environment, and for our communities." Key highlights from the 2024 Sustainability Report include: Resilient Operations: Met 11% of annual global electricity needs with renewable energy. Installed more than 5,700 rooftop solar panels at the new manufacturing facility in Malaysia, meeting 21% of the facility's electricity needs after they were brought online. Malaysia facility designed to achieve both Green Building Index (GBI) and Leadership in Energy and Environmental Design (LEED) Silver certifications. Sustainable Product Innovation: Continued the U.S. Pod takeback pilot in Massachusetts and expanded the pilot to California. Accepted 7.4 million Pods through global product takeback programs. Developed a long-term roadmap to create efficient and sustainable packaging. People and Communities: Expanded access to Omnipod 5 internationally and through integration with Abbott's FreeStyle Libre 2 Plus and Dexcom G7 sensors, and in the U.S., we launched the Omnipod 5 App for iPhone. Introduced Insulet's Ways of Working to empower teams and foster cross functional collaboration while providing exceptional customer and employee experiences. Launched "Insulet for Good," a global corporate giving program, surpassing goals for employee engagement and volunteer hours. The 2024 Sustainability Report can be found on and About Insulet Corporation: Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet's flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit or ©2025 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation. All rights reserved. The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott and used with permission. Dexcom is a registered trademark of Dexcom, Inc. and used with permission. All other trademarks are the property of their respective owners. View source version on Contacts Investor Relations: June LazaroffSenior Director, Investor Relations(978) 600-7718jlazaroff@ Media: Angela Geryak WiczekSenior Director, Corporate Communications(978) 932-0611awiczek@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
